We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

143 hedge funds and large institutions have $124M invested in Nektar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,260% more call options, than puts

Call options by funds: $218K | Put options by funds: $5K

40% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 35

31% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 16

4% more funds holding

Funds holding: 138 → 143 (+5)

0.3% less ownership

Funds ownership: 5.1% → 4.8% (-0.3%)

32% less capital invested

Capital invested by funds: $183M → $124M (-$59.4M)

Holders
143
Holders Change
+5
Holders Change %
+3.62%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
49
Reduced
35
Closed
16
Calls
$218K
Puts
$5K
Net Calls
+$213K
Net Calls Change
+$54K

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$4.35M
2
WP
Woodline Partners
California
+$3.81M
3
ACM
Altium Capital Management
New York
+$3.51M
4
2L
22NW LP
Washington
+$2.58M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.82M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$16.4M
2
Citadel Advisors
Citadel Advisors
Florida
-$7.71M
3
EAM
Eventide Asset Management
Massachusetts
-$3.23M
4
SC
Shay Capital
New York
-$1.46M
5
AI
Acuitas Investments
Washington
-$1.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
126
Federated Hermes
Pennsylvania
$1.17K – – –
BBHC
127
Brown Brothers Harriman & Co
New York
$930 – – –
WA
128
Whipplewood Advisors
Colorado
$744 +$935 +53 New
ACA
129
Atlas Capital Advisors
Wyoming
$558 +$705 +40 New
GRP
130
Global Retirement Partners
California
$387 +$476 +27 +2,700%
Jones Financial Companies
131
Jones Financial Companies
Missouri
$372 +$476 +27 New
AWM
132
AllSquare Wealth Management
New York
$258 – – –
Nisa Investment Advisors
133
Nisa Investment Advisors
Missouri
$187 -$141 -8 -38%
KB
134
Kimelman & Baird
New York
$186 – – –
S
135
SignatureFD
Georgia
$186 – – –
AG
136
AmeriFlex Group
Nevada
$165 +$229 +13 New
EWA
137
EverSource Wealth Advisors
Alabama
$159 +$194 +11 New
VCM
138
Versant Capital Management
Arizona
$157 – – –
HI
139
Harbour Investments
Wisconsin
$144 – – –
MWA
140
Medallion Wealth Advisors
Connecticut
$141 +$247 +14 New
SL
141
Salomon & Ludwin
Virginia
$43 – – –
SPIA
142
Steward Partners Investment Advisory
New York
$37 – – –
SS
143
SBI Securities
Japan
$13 +$18 +1 New
CPG
144
Cornerstone Planning Group
New Jersey
$4 – – –
HNB
145
Huntington National Bank
Ohio
$1 – – –
AI
146
Acuitas Investments
Washington
– -$1.43M -73,096 Closed
Balyasny Asset Management
147
Balyasny Asset Management
Illinois
– -$390K -20,023 Closed
ECM
148
ExodusPoint Capital Management
New York
– -$364K -18,691 Closed
GCP
149
GSA Capital Partners
United Kingdom
– -$279K -14,283 Closed
Jane Street
150
Jane Street
New York
– -$119K -6,098 Closed
3 4 5
6
7

NKTR Hedge Fund Activity: Q4 2024 in Review

143 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2024, worth a combined $124M — down 32% from $183M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new NKTR positions and 16 closed out — a net gain of 5 holders — while 49 added to existing stakes and 35 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $4.35M. The largest seller was Deep Track Capital, cutting an estimated $16.4M.

  • 143 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2024, up from 138 in Q3 2024.
  • Funds reported $124M of Nektar Therapeutics stock for Q4 2024, down 32% quarter-over-quarter.
  • 21 funds opened new Nektar Therapeutics positions in Q4 2024 and 16 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q4 2024 was Nantahala Capital Management, an estimated $4.35M added.
  • The largest Nektar Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2024.